Advertisement

Topics

Neuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017 [Report Updated: 01082017] Prices from USD $3995

09:50 EDT 2 Aug 2017 | BioPortfolio Report Blog

Neuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017

Summary

This report provides an overview of the pipeline landscape for neuropsychiatric disorders. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Attention Deficit Hyperactivity Disorder ADHD, Depression, Schizophrenia, and Tourette syndrome, and features dormant and discontinued projects.

Attention deficit hyperactivity disorder ADHD is a group of behavioral symptoms that include inattentiveness, hyperactivity and impulsiveness, with symptoms including disorganized work habits, procrastination and inability to sustain attention on tasks or activities.

Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. Signs and symptoms include sleep disturbances, including insomnia or sleeping too much, changes in appetite, anxiety, agitation or restlessness and physical problems, such as back pain or headaches.

Schizophrenia is a chronic, severe, and disabling brain disorder that generally appears in late adolescence or early adulthood. Symptoms include delusions, hallucinations, disorganized speech and disorganized behavior.

Finally, Tourette syndrome is a neurological disorder characterized by repetitive, stereotyped, involuntary movements and vocalizations called tics. Symptoms include eye blinking and other eye movements, facial grimacing, shoulder shrugging, and head or shoulder jerking.

The size of these pipelines ranges from 11 products in Tourette syndrome to 191 in depression. Across all four of these indications, however, transporters and receptors of neurotransmitters such as dopamine and serotonin are the most common targets, closely reflecting the current treatment landscape of these diseases.

Scope

Which companies are the most active within the pipeline for genetic neuropsychiatric disorder therapeutics?
Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
What are the most important RD milestones and data publications to have happened in the field of genetic neuropsychiatric disorders?

Reasons to buy

Understand the overall pipeline, with an ataglance overview of all products in therapeutic development for each indication
Assess the products in development in granular detail, with an uptodate overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Original Article: Neuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017 [Report Updated: 01082017] Prices from USD $3995

NEXT ARTICLE

More From BioPortfolio on "Neuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017 [Report Updated: 01082017] Prices from USD $3995"

Quick Search
Advertisement
 

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Attention deficit hyperactivity disorder (ADHD)
Attention deficit hyperactivity disorder (ADHD) is a group of behavioural symptoms that include inattentiveness, hyperactivity and impulsiveness. Attention deficit disorder (ADD) is a sub-type of ADHD - symptoms of ADHD include: a short attenti...